Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
383
datasets available to search
ShareScore release 0.9.0
Dataset results
383 results for “GVHD”
Evaluation of Antifungal Prophylaxis on Graft-versus-host Disease (GVHD) Patients
ClinicalTrials.gov study NCT01282879. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies
ClinicalTrials.gov study NCT03270748. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Data from: Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans
Allogeneic antibodies against minor histocompatibility antigens encoded on the Y chromosome (HY-Abs) develop after hematopoietic cell transplant (HCT) of male recipients with female donors (F→M). However, the temporal association between HY-Ab development and chronic graft-versus-host disease (cGVHD) has yet to be elucidated. We studied 136 adult F→M HCT patients, with plasma prospectively collected through 3 years posttransplant, and measured immunoglobulin G against 6 H-Y antigens. Multiple HY-Abs were frequently detected beginning at 3 months posttransplant: 78 (57%) of F→M patients were seropositive for at least 1 of the 6 HY-Abs, and 3-month seropositivity for each HY-Ab was associated with a persistent seropositive response throughout the posttransplant follow-up period (P < .001 in each). There were no associations between pretransplant features and 3-month overall HY-Ab development. Detection of multiple HY-Abs at 3 months (represented by HY score) was significantly associated with an increased risk of cGVHD (P < .0001) and nonrelapse mortality (P < .01). Compared to clinical factors alone, the addition of HY score to clinical factors improved the predictive potential of cGVHD (P < .01). Monitoring HY-Ab development thus stratifies cGVHD risk in F→M HCT patients and may support preemptive prophylaxis therapy for cGVHD beginning at 3 months posttransplant.
The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant
ClinicalTrials.gov study NCT03805789. IPD Sharing: YES. Countries: 8. Publications: 0.
Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation
ClinicalTrials.gov study NCT00548717. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT
ClinicalTrials.gov study NCT01220297. IPD Sharing: NO. Countries: 1. Publications: 0.
Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil
ClinicalTrials.gov study NCT00608517. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Ablative Fractional Laser for Sclerotic GVHD-Associated Joint Contractures
ClinicalTrials.gov study NCT02881047. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD
ClinicalTrials.gov study NCT04446182. IPD Sharing: NO. Countries: 1. Publications: 0.
Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)
ClinicalTrials.gov study NCT00506948. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT
ClinicalTrials.gov study NCT01246206. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Haplo Peripheral Blood Sct In GVHD Prevention
ClinicalTrials.gov study NCT04473911. IPD Sharing: YES. Countries: 1. Publications: 0.
GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conventional 8/8 HLA-matched Related or Unrelated Donor Allogeneic Hematopoietic Stem Cell Tra
ClinicalTrials.gov study NCT02360111. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD)
ClinicalTrials.gov study NCT01111526. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Campath in Chronic GVHD
ClinicalTrials.gov study NCT00495755. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation
ClinicalTrials.gov study NCT00429416. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Alpha 1 Anti-Trypsin (AAT) in Treating Patients With Acute Graft-Versus-Host Disease GVHD)
ClinicalTrials.gov study NCT01523821. IPD Sharing: NO. Countries: 1. Publications: 0.
Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD
ClinicalTrials.gov study NCT02411084. IPD Sharing: Not stated. Countries: 7. Publications: 0.
High-Dose Cyclophosphamide for Steroid Refractory GVHD
ClinicalTrials.gov study NCT00492921. IPD Sharing: NO. Countries: 1. Publications: 0.
Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD
ClinicalTrials.gov study NCT02322190. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.